NASDAQ · PHARMACEUTICAL PREPARATIONS · SMALL CAP
Cervomed Inc. CRVO
16 fiscal years on record · USD · FY2025 reported
SEC FILINGS ONLY
Revenue · FY2025
$4.0M
▼ 58.9% vs FY2024
EPS · FY25
—
Dividend / sh · FY25
—
Payout · FY25
—
ROE · FY25
-93.9%
Net margin · FY25
-673.1%
Dividend coverage
—
Advertisement
AdSense · Leaderboard 728×90320×100
Result
USD 4.0M
Revenue, FY2025 · full 16-year series below
Revenue
Net income
The company lost 673 cents on every revenue dollar this year.
Per share
—
Diluted EPS, FY2025
EPS
The company pays no cash dividend.
Profitability
-93.9%
Return on equity, FY2025
ROE
Operating margin-706.2%
Net margin-673.1%
Return on assets-81.8%
Each USD of equity lost 94 cents this year.
Returned to shareholders
—
returned in FY2025 · dividends + net buybacks
Dividends paid—
Net buybacks—
Share of profit—
Consecutive raises—
Growth
—
revenue, compounded over five years
CAGR
3 yrs
5 yrs
10 yrs
15 yrs
Revenue
+35.9%
Compound annual rates per period — left blank where the series crosses a loss.
Share base
0.01B
Shares outstanding, FY2025
Change, 5 years—
Change, 10 years—
A share split breaks the comparison across the period, so we leave it out.
Advertisement
AdSense · Leaderboard 728×90300×250
Balance sheet
USD 22.9M
total assets, end of FY2025
Total assetsUSD 22.9M
EquityUSD 18.2M
CashUSD 8.2M
Current ratio4.91×
Equity funds 80% of total assets.
History
16 fiscal years
Every figure from documents filed with the SEC · USD
Metric
2025
2024
2023
2022
2021
2020
2019
2018
2017
2016
2015
2014
2013
2012
2011
2010
Revenue $B
0.0
0.0
0.0
0.0
·
·
·
·
·
·
·
·
0.0
0.0
0.0
0.0
Operating income $B
−0.0
−0.0
−0.0
−0.0
−0.0
−0.0
−0.0
−0.0
−0.0
−0.0
−0.0
−0.0
−0.0
−0.0
−0.0
−0.0
EBITDA $B
·
·
·
−0.0
−0.0
−0.0
−0.0
−0.0
−0.0
−0.0
−0.0
−0.0
−0.0
−0.0
−0.0
−0.0
Income tax $B
0.0
·
·
0.0
−0.0
−0.0
0.0
−0.0
−0.0
−0.0
0.0
−0.0
0.0
0.0
·
·
Net income $B
−0.0
−0.0
−0.0
−0.0
−0.0
−0.0
−0.0
−0.0
−0.0
−0.0
−0.0
−0.0
−0.0
−0.0
−0.0
−0.0
EPS, diluted $
·
·
·
2038891.00
1946859.00
53831973.00
6706509.00
3242301.00
−29.11
−1.76
−2.56
−1.00
−1.00
−8.16
−0.26
−0.14
Dividend / sh $
·
·
·
·
·
·
·
·
·
·
·
·
·
·
·
·
Payout %
·
·
·
·
·
·
·
·
·
·
·
·
·
·
·
·
ROE %
−93.9
−69.9
·
−713.6
−80.7
−63.1
−66.0
−99.7
−9.0
−394.5
−35.2
−64.3
·
·
·
·
Shares out B
0.01
0.01
0.01
0.00
0.00
0.06
0.03
0.00
0.00
0.01
0.01
0.02
0.01
0.00
0.09
0.06
Slide the table for earlier years · "·" marks figures not disclosed in the filing for that year.
How we verifyAUDITED
49 of 49
checks passed before publication
EPS recomputationBalance-sheet identityGross profitBalance-sheet liquidity
Every figure was compared against the original statement: 0 failures and 0 presentation gaps.
What we don’t show
We’d rather say what’s missing than fill the gap with an estimate.
P/E rationeeds a market quote — not yet licensed
Market capitalizationneeds a market quote — not yet licensed
Dividend yieldneeds a market quote — not yet licensed
Price-to-bookneeds a market quote — not yet licensed